Literature DB >> 29673828

Decision-making for the treatment of climacteric symptoms using the Menopause Rating Scale.

Juan Enrique Blümel1, Eugenio Arteaga2, Joaquín Parra3, Carolina Monsalve3, Valentina Reyes3, María Soledad Vallejo4, Rosa Chea3.   

Abstract

OBJECTIVE: The Menopause Rating Scale (MRS) is one of the most frequently used instruments to evaluate menopausal symptoms; however, no cut-off score is given that would indicate the need for treatment. Our goal was to determine such a cut-off score on the MRS, using as a standard a woman's own perception of her need for treatment in relation to the severity of her symptoms.
MATERIAL AND METHODS: The sample comprised 427 healthy women aged 40-59 years who were not taking hormonal treatment. Based on the concept of quality of life, we considered that the patient required treatment if she herself believed that she required it, on the basis of the severity of at least one of her menopausal symptoms. To obtain an optimal MRS cut-off score associated with the need for treatment, an ROC curve analysis was performed.
RESULTS: The symptoms rated "very severe" on the MRS (i.e. that most require treatment) were physical and mental exhaustion (95.8% of women) and muscle and joint discomfort (95.1%). In total, 378 women (88.5%) considered that their symptoms required treatment. The ROC curve analysis determined that the optimal cut-off score on the MRS to indicate the need for treatment would be 14 (area under the curve 0.86, p < 0.0001). This score achieved 76.5% sensitivity and 83.6% specificity. With this cut-off score, 97.1% of the women who considered that they required treatment for at least one of their symptoms would be treated. There was concordance of more than 90% between this cut-off score and a score of 4 (i.e. a rating of "very severe") for any of the symptoms on the scale.
CONCLUSIONS: An MRS score ≥14 indicates the need for treatment for climacteric symptoms. In clinical practice, a score of 4 for any of the MRS items could be taken to indicate the need for treatment.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Climacteric symptoms; Menopause Rating Scale; Menopause therapy; Patient decision-making

Mesh:

Year:  2018        PMID: 29673828     DOI: 10.1016/j.maturitas.2018.02.010

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  6 in total

1.  Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial.

Authors:  Patricia Loranca-Moreno; Juan Moises Ocampo-Godínez; Alan Rios-Espinosa; Magdalena Cruz-Luna; Carolina Garmendia-Gallardo; Merle Yasmin Hernández-Castañón; Verónica Yazmin Hernández-Hernández; Paula Mariana Sánchez-Tinoco; Alma Bajonero-Domínguez; Jael Adrián Vergara Lope-Núñez; Marco Antonio Álvarez-Pérez; José Luis González-Quiroz
Journal:  Arch Gynecol Obstet       Date:  2022-08-23       Impact factor: 2.493

Review 2.  Correlates of palpitations during menopause: A scoping review.

Authors:  Janet S Carpenter; Ying Sheng; Caitlin Pike; Charles D Elomba; Jennifer S Alwine; Chen X Chen; James E Tisdale
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec

Review 3.  Review of menopausal palpitations measures.

Authors:  Ying Sheng; Janet S Carpenter; Charles D Elomba; Jennifer S Alwine; Min Yue; Caitlin A Pike; Chen X Chen; James E Tisdale
Journal:  Womens Midlife Health       Date:  2021-05-31

4.  Evaluating the Effects of Symptom Monitoring on Menopausal Health Outcomes: A Systematic Review and Meta-Analysis.

Authors:  Robin Andrews; Gabrielle Hale; Bev John; Deborah Lancastle
Journal:  Front Glob Womens Health       Date:  2021-12-03

Review 5.  Assessment of the climacteric syndrome: a narrative review.

Authors:  Marina Sourouni; Martina Zangger; Livia Honermann; Dolores Foth; Petra Stute
Journal:  Arch Gynecol Obstet       Date:  2021-07-06       Impact factor: 2.344

6.  The relationship between management strategies for menopausal symptoms and women's decision making styles during menopausal transition.

Authors:  Narjes Bahri; Moosa Sajjadi; Leila Sadeghmoghadam
Journal:  Prz Menopauzalny       Date:  2019-12-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.